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Plasmodium sporozoites and liver stages express antigens that are targeted to
the MHC-Class I antigen-processing pathway. After the introduction of Plasmodium
sporozoites by Anopheles mosquitoes, bone marrow-derived dendritic cells in
skin-draining lymph nodes are the first cells to cross-present parasite antigens and elicit
specific CD8+ T cells. One of these antigens is the immunodominant circumsporozoite
protein (CSP). The CD8+ T cell-mediated protective immune response against CSP is
dependent on the interleukin loop involving IL-4 receptor expression on CD8+ cells and
IL-4 secretion by CD4+ T cell helpers. In a few days, these CD8+ T cells re-circulate to
secondary lymphoid organs and the liver. In the liver, the hepatic sinusoids are enriched
with cells, such as dendritic, sinusoidal endothelial and Kupffer cells, that are able to
cross-present MHC class I antigens to intrahepatic CD8+ T cells. Specific CD8+ T cells
actively find infected hepatocytes and target intra-cellular parasites through mechanisms
that are both interferon-γ-dependent and -independent. Immunity is mediated by CD8+
T effector or effector-memory cells and, when present in high numbers, these cells can
provide sterilizing immunity. Human vaccination trials with recombinant formulations or
attenuated sporozoites have yet to achieve the high numbers of specific effector T cells
that are required for sterilizing immunity. In spite of the limited number of specific CD8+
T cells, attenuated sporozoites provided multiple times by the endovenous route provided
a high degree of protective immunity. These observations highlight that CD8+ T cells may
be useful for improving antibody-mediated protective immunity to pre-erythrocytic stages
of malaria parasites.
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INTRODUCTION
Malaria is a vector-born, parasitic illness caused by infection
with Plasmodium spp. More than 3 billion individuals live in
the endemic areas, which are mainly in tropical areas of the
world. The disease causes approximately 600,000 annual deaths
and most individuals are children living in Africa. In adults, preg-
nant women are vulnerable to malaria as pregnancy reduces their
immunity. This problem has long been neglected but thematernal
malaria causes an increased risk of spontaneous abortion, pre-
mature delivery and low birth weight of the fetus (Cotter et al.,
2013; WHO Malaria Policy Advisory Committee and Secretariat,
2013; White et al., 2014). Plasmodium parasites have a complex
Abbreviations: PAMPs, Pathogen-associated molecular patterns; GPI,
Glycosylphosphatidylinositol; TLR, Toll-like receptor; CSP, Circumsporozoite
protein; RON4, Rhoptry resident protein; TRAP, Thrombospondin-related
adhesion protein; ME-TRAP, Multiple epitope-thrombospondin-related adhesion
protein; TLP, TRAP-Like Protein; TREP, TRAP-related protein; SPATR, Surface
protein containing an altered thrombospondin repeat domain; AMA1, Apical
membrane antigen 1; TAP, Vacuolar complex peptide transporters; LSA1, Liver-
stage antigen 1; CelTOS, Cell-traversal protein for sporozoites; MVA, Modified
vaccinia Ankara virus; AdHu5, Human type 5 replication-deficient adenovirus;
TEM, Effector memory T cells; TCM, Central memory T cells; DC, Dendritic cell;
LC, Langerhans cell; SC, Sinusoidal endothelial cells; KC, Kupffer cell.
life cycle, and the disease begins by the bite of an infected female
Anopheline mosquito carrying the sporozoite form, which is
the pre-erythrocytic stage of Plasmodium parasites. Plasmodium
sporozoites are released from the secretory duct of the vector sali-
vary gland where they develop and are injected into the bite site
of the skin during blood meals. In the epidermis, the sporozoites
actively cross the capillary vessels to enter the bloodstream from
where they reach the liver (Khan and Waters, 2004; Miller et al.,
2013).
After reaching the liver parenchyma, the sporozoites invade
hepatocytes to divide and produce thousands of merozoites,
which are the erythrocytic forms of Plasmodium parasites
(Prudêncio et al., 2006). Parasite growth inside hepatocytes causes
host cellular rupture, releasing the merozoites into the blood-
stream, where they subsequently invade erythrocytes to initiate
a cycle of intra-erythrocytic stage development. In this stage,
the Plasmodium parasites continuously grow inside red blood
cells, causing rupture and re-invasion of healthy erythrocytes and
resulting in increased numbers of parasites in the bloodstream
every 48 h (Prudêncio et al., 2006; Wright and Rayner, 2014).
Unlike the erythrocytic-stage of Plasmodium infection, which
is responsible for the clinical symptoms and pathology of the
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disease, the liver stage of malaria is clinically silent but signifi-
cantly relevant in the point of view of the host immune defense
mechanisms (Frevert and Nardin, 2008). The hepatocyte cells are
an obligatory destination for schizogony during the intrahepatic
stage, which lasts for 2–7 days, depending on the mammalian
host (5–10 days in humans), thus allowing the protective, cell-
mediated immune responses to target the reservoirs of parasites in
the liver. These hepatic reservoirs are a crucial target for immuno-
logical intervention achievements, as efficacious and effective
pre-erythrocytic stage immunity would prevent the release of
parasites from the hepatocyte and, consequently, the develop-
ment of clinical disease and transmission of malaria (Doolan
and Martinez-Alier, 2006; Duffy et al., 2012). The most clini-
cally advanced malaria vaccine candidates for preventing disease
are based on liver-stage Plasmodium antigens able to initiate pro-
tective immune responses and are expected to target endemic
areas of greatest disease burden (Duffy et al., 2012; Birkett et al.,
2013).
ANOPHELES VECTOR TRANSMISSION OF PLASMODIUM
PARASITES IN THE SKIN SETS THE FIRST STAGE FOR
INDUCTION OF CD8+ T CELL-MEDIATED IMMUNITY
AGAINST MALARIA SPOROZOITES
The sporozoite parasites are differentiated in the salivary glands
of the mosquito vector and are inoculated in the vertebrate skin
as the mosquito probes to locate the capillary vessels during the
blood meal. During this phase, the sporozoites are injected into
the skin tissue, a process that ends when the proboscis of the
vector reaches the blood circulation and salivation no longer
takes place (Vanderberg, 2014). Once in the skin, the sporo-
zoites face a dangerous journey to the liver. They must find
their way to hepatocytes, where they develop to the erythro-
cytic stage. Once the sporozoites enter the skin, the parasites are
immediately targeted by innate host immune responses. Besides
its own antigenic properties, the saliva proteins of the vector
can influence several physiological responses in the skin, as the
salivary contents have immunomodulatory properties (Demeure
et al., 2005; Beghdadi et al., 2008; Hayashi et al., 2012; Mecheri,
2012).
The tissue trauma generated from the arthropod bite set-
tles the cutaneous immune response behavior at the beginning
of infection, as this injury generates endogenous danger signals
(danger-associated molecular patterns) that, together with the
exogenous PAMPs associated with Plasmodium parasites, play a
crucial role in the initiation of the immune response (Naik et al.,
2000; Gowda, 2007; Erdman et al., 2008; Greene et al., 2009;
Fu et al., 2012; Gbédandé et al., 2013). While blood stage para-
site PAMPs such as GPI or hemozoin/DNA have been identified
(Gowda, 2007; Erdman et al., 2008), sporozoite PAMPs that could
play a role in the skin remain to be defined. Thus, parasite-host
factors during vector-mediated malaria transmission could be
a determinant for activating the innate immune responses that
would have an impact in the onset of parasite-specific adaptive
immunity (Coban et al., 2007; Franklin et al., 2009; Gowda et al.,
2012).
The arthropod vector also plays a role on this battlefield
scenario because the Anopheles mosquito harbors an associated,
symbiotic microbiome that is beneficial to host life related-
traits, such as development, fecundity dietary, adaptation to the
environment and immunity against pathogenic microorganisms,
including Plasmodium parasites, in its digestive tract (Dinparast
Djadid et al., 2011; Wang et al., 2011; Alvarez et al., 2012; Jiang
et al., 2012; Ngwa et al., 2013). Glycosylphosphatidylinositol
of Plasmodium parasites works as an exogenous PAMP to pro-
mote host cellular pro-inflammatory responses, mainly via TLR2
(Gowda, 2007). It is possible that, during the mosquito bite, the
sporozoites are injected with an assortment of symbiotic microor-
ganisms into the skin. Therefore, the mosquito microbiome itself
could potentiate the innate signaling mechanisms involved in the
skin immunity.
Recent studies using an experimental mousemodel for malaria
infection have substantially increased our comprehension of the
host cellular responses that occur in cutaneous tissues during
an Anopheles mosquito bite. An initial report has shown evi-
dence that mosquito bites promote mast cell degranulation,
leading to increased vascular permeability with plasma leak-
age and leukocyte infiltration into the injured tissue (Depinay
et al., 2006). These host responses are initially followed by an
accumulation of CD3+ and B220+ lymphocytes and CD11c+
dendritic cells in the skin-draining lymphoid tissues, leading
to hyperplasia of the organ at a time when no prolifera-
tion of these cells is observed, indicating a local sequestration
of leukocytes from peripheral lymph nodes (Demeure et al.,
2005).
These findings demonstrate that the subcutaneous trans-
mission of the parasite by the vector potentially generates all
of the requirements for priming the host adaptive immune
responses in skin-associated tissues. However, no study has
demonstrated how the antigens are processed in the tissue-
nature source of the antigen-presenting cells that are retained
in the skin-draining lymphoid organs after vector transmis-
sion of Plasmodium sporozoites. It is possible that the accumu-
lated dendritic cell population in the skin-associated draining
lymph nodes, which is critical for the priming of protective
CD8+ T cells against Plasmodium sporozoites, is derived from
the cutaneous sites where the parasites are inoculated during a
mosquito bite. All dendritic cell subsets of skin-draining lymph
nodes are defined by the expression of the CD205, CD11b,
CD11c, and CD8 markers, including a presumably blood-borne
lymph node resident, CD8+CD207+ Langerhans cell popula-
tion (Henri et al., 2010; Fehres et al., 2013). It remains unclear
whether this cell population can transport antigens to lymph
nodes and promote the initiation of T cell responses or, alter-
natively, if the parasite or its antigens can directly reach the
skin-draining lymph nodes that are drained through the conduit
network.
Recent studies using CD8+ T cell transgenic mice specific for
a MHC class I epitope present in the immunodominant sur-
face protein of the sporozoite, the CSP, indicate that, in fact,
the first signal of priming for the parasite-specific CD8+ T cell
response originates from the skin-draining lymphoid tissues asso-
ciated with the site of vector transmission where the Plasmodium
sporozoites are also found (Yamauchi et al., 2007).Within the first
48 h, these epitope-specific CD8+ T cells secrete IFN-γ in lymph
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nodes draining the site where the parasite was injected either by a
vector bite or by dermal needle injection of the Plasmodium par-
asites (Chakravarty et al., 2007; Sinnis and Zavala, 2012; Ménard
et al., 2013). However, in these experimental model studies, the
parasites used in the infection were attenuated by irradiation, a
matter that could change its infectivity in the skin because it has
been shown that potent gliding motility is crucial for sporozoite
exit from the cutaneous tissue (Vanderberg, 2014). These studies
highlight the importance of the skin in the early stage of infection
during the priming of the protective CD8+ T cell responses that
ultimately will limit the success of the parasite to reach the liver,
where its multiplies and establishes its reservoir to continue to the
blood-phase of infection.
THE HEPATIC ENVIRONMENT AS A SPECIALIZED NICHE
CONSTITUTED WITH PROFESSIONAL
ANTIGEN-PROCESSING CELLS FOR MHC CLASS I ANTIGENS
Studies have revealed that the time from the infective bite to
the arrival of the parasite in the liver is approximately one to a
few hours (Vanderberg, 2014). During this phase, the parasites
must be prepared for the grand finale moment that culminates in
the invasion of hepatocyte. Microarray analysis of the sporozoite
transcriptome indicated a differential gene expression profile in
the salivary gland forms compared to the sporozoites co-cultured
with hepatocyte cells. In these studies, 21 genes were confirmed
to be up-regulated in sporozoites co-cultured with hepatocytes.
These genes were clustered into two patterns of expression, one
transiently up-regulated and the other with sustained, increased
expression (Rosinski-Chupin et al., 2007; Mikolajczak et al.,
2008). These different expression profiles indicate genes that
express sporozoite surface proteins that are involved in hepa-
tocyte invasion and transiently expressed and other sustained-
expression genes that are involved in the development of parasites
inside hepatocytes (Mikolajczak et al., 2008).
Recently, it has been determined that, in fact, there is a shift
in the sporozoite forms from the arthropod vector to the mam-
malian host that is responsible for the activation of the steady-
state form of the parasite to its adaptation to the hepatic stages
(Coppi et al., 2011). Migrating sporozoites switch to an inva-
sive phenotype in the vertebrate host to reach and colonize the
liver. This is well demonstrated in the context of the circumsporo-
zoite protein, which is required for the interaction of the parasite
with hepatocyte cells. In salivary glands, the CSP expressed by the
sporozoites has a masked domain at its carboxy terminus. During
its adaptation in the vertebrate host, the CSP is proteolytically
processed in the liver tissue, thus exposing its C-terminal domain,
which binds to heparan sulfate proteoglycans on the hepatocyte
membrane as the parasite contacts these target cells during hep-
atic invasion (Coppi et al., 2011). This process is responsible for
changing the status of the sporozoite into a hepatic invasive form,
which contrasts from the skin form in that the cell transversal
activity is the most important mechanism responsible for parasite
invasion.
In the liver parenchyma, the parasite needs to glide through
tissues and transverse hepatocytes (Ishino et al., 2004). However,
this mechanism is not required for final hepatocyte invasion
of the parasite before entering the intra-hepatic developmental
stage (Ishino et al., 2004, 2005; Kariu et al., 2006; Amino et al.,
2008). The invasion mechanism for this step has been shown
to be dependent on the recognition of receptors for the region
II-plus of the CSP on the basolateral domain of the plasma mem-
brane of hepatocytes (Cerami et al., 1992) and the expression of
genes such as the RON4 and the trombospondin-related adhe-
sive proteins TRAP, TREP, TLP, and SPATR, which have roles
in sporozoite motility and binding to hepatocyte cells (Sultan
et al., 1997; Moreira et al., 2008; Combe et al., 2009). Inside
hepatocytes, the sporozoites reside adjacent to the nucleus, and
it has been suggested that this topological location may be use-
ful for the parasite’s control of the host cells, which occurs by
translocation of the CSP into the host nucleus to modulate hep-
atocyte gene transcription (Singh et al., 2007). During the liver
stage, the Plasmodium is highly metabolically active and expresses
several genes to support its growth and development to blood-
stage merozoites (Duffy et al., 2012). It has been shown that
the gene products of liver-stage sporozoites are accessible to the
host MHC class I-dependent antigen-processing machinery that
is required for CD8+ T cell recognition and are thus considered
potential vaccine targets against the disease (Birkett et al., 2013).
Among these genes, the immunogenic properties of Plasmodium
liver-stage antigen-1 have been investigated, and this antigen has
been currently evaluated in vaccine protocols aimed at induc-
ing protection from malaria liver-stage parasites (Hill et al., 1992;
Pichyangkul et al., 2008; Rodríguez et al., 2009; Cummings et al.,
2010).
The choice of liver-stage development genes as vaccine targets
seems to be of relevance because the antigens can be expressed
early or late during parasite development in the liver, thus varying
the efficacy of the immunity to the infected hepatocytes. However,
the paucity of liver-stage, parasite-specific epitopes that are rec-
ognized by CD8+ T cells has constrained vaccine development
approaches. Several preclinical evaluations strongly support the
importance of CSP-based vaccine approaches to confer protection
mediated by CD8+ T cells, but this remains to be determined in
humans (Zavala et al., 1985; Khusmith et al., 1991; Kumar et al.,
2006). Recently, studies using genome-wide epitope profiling have
identified new potential antigen targets in the TRAP (Hafalla
et al., 2013). These epitope-mapping studies should improve the
design of vaccine protocols based on recombinant viral vectors
and DNA vaccines encoding the entire TRAP antigen sequence,
which have been shown to induce a protective-mediated immune
response against malaria liver-stage infection (Ewer et al., 2013;
Ferraro et al., 2013; Hafalla et al., 2013).
Importantly, it has been shown that, besides the early
expressed antigens by liver-stage sporozoite forms, such as the
TRAP and CS genes, late antigens expressed during the intra-
hepatic development of blood-stage merozoites inside hepato-
cytes are also targets of the host-protective CD8+ T cell responses.
Virus-vector vaccines expressing the AMA1 from Plasmodium
parasites induce sterile protection associated with cell-mediated
immunity (Chuang et al., 2013; Schussek et al., 2013; Schwenk
et al., 2013). AMA1 is a highly conserved antigen in all apicom-
plexa parasites and is expressed in the merozoite stage of the
Plasmodium life cycle (Remarque et al., 2008). During the intra-
hepatic stage of Plasmodium parasites, this antigen is expressed in
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the late-stage of development of sporozoite forms to the mero-
zoite blood stage. In mice, vaccine-induced AMA1-specific CD8+
T cells are associated with sterile protection against experimental
malaria infection. In humans vaccinated with a combined genetic
vaccine expressing AMA-1 and CSP of P. falciparum, 4 of the 15
volunteers (27%) were sterile protected against infection caused
by infected mosquito bites (Chuang et al., 2013). Based on these
findings, it is worthy to speculate that a better approach for vac-
cine design should combine the use of antigen targets expressed
during the early stages of parasite infection in hepatocytes, e.g.,
the CSP and TRAP antigens, with the late-expressed AMA1 anti-
gen from Plasmodium parasites to potentiate the effectiveness of a
vaccine against malaria liver-stage infection.
The exposure of infected hepatocytes to sporozoites devel-
oping antigens in the course of infection has been proposed as
important for the acquisition of anti-malaria adaptive immune
responses, but the basis of hepatocyte antigen processing and
presentation are not well understood. Recent studies have inves-
tigated the effects of parasite replication on the MHC class I
pathway in hepatocytes. A HC-04 cell line isolated from primary
human hepatocytes supports the full development of Plasmodium
falciparum and Plasmodium berghei sporozoites to exoerythro-
cytic merozoite forms in the same time frame as observed in vivo
(Ma et al., 2013). In these studies, Levitskaya’s group has demon-
strated that infected human hepatocytes supporting the replica-
tion and development of Plasmodium parasites to merozoites did
not change the mRNA expression of the molecular components
of the MHC class I pathway, such as the non-proteolytic (α1
and α2) and proteolytic (β1, β2, and β5) subunits of the proteo-
some, the elements of the TAP1 and TAP2 that are involved in the
non-classical MHC class I cross-presentation pathway of vacuo-
lar antigens, or ER chaperones (calnexin, calreticulin and Erp57)
responsible for the complex assembly and stability of MHC class I
molecules (Ma et al., 2013). These studies also demonstrated that
infected hepatocytes were able to up-regulate the surface expres-
sion of MHC class I molecules in response to pro-inflammatory
IFN-γ and TNF-α cytokines.
Interestingly, the findings indicated that human hepatocytes
infected with Plasmodium parasites express the MHC class I
processing and presentation machinery of the cross-presenting
pathway and are able to stimulate and induce the activation of
antigen-specific MHC class I-restricted effector CD8+ T cells
(Balam et al., 2012). This phenomenon is of relevance because
it has been shown that the in vivo activation of CD8+ T cells spe-
cific for CS depends on the cross-presentation of parasite antigens
to the class I vacuolar pathway via TAP1 (Cockburn et al., 2011).
However, it is important to note that, as the CS protein is an early
antigen expressed by the sporozoite liver stages, it is possible that
the antigen-processing restriction for the antigens expressed in
the late-phase, intra-hepatic developmental stages of Plasmodium
parasites may have different restrictions and pathways.
The cross-presentation MHC class I pathway in the liver seems
to be extended to different subsets of hepatic cells, and this func-
tion was observed in liver sinusoidal endothelial cells as well as
Kupffer cells at low antigen concentrations (Ebrahimkhani et al.,
2011). Interestingly, the antigen cross-presentation by liver cells
induced efficient CD8+ T cell expansion comparable to classical
dendritic cells obtained from the spleen (Plebanski et al., 2005;
Ebrahimkhani et al., 2011). However, T cells that proliferated fol-
lowing activation by contact with antigen-presenting liver cells
expressed lower levels of T cell activation markers and intracel-
lular IFN-γ, suggesting that dendritic cells may have a role in
compensating the full activation program of CD8+ T cells that
are initially activated in the hepatic parenchyma (Ebrahimkhani
et al., 2011), a scenario that could support the full priming of
CD8+ T cells in the liver. Alternatively, it is possible that the pri-
mary CD8+ T cells activated in the draining lymphoid organs
during skin infection may support further activation and dif-
ferentiation by liver cells once the parasite targets the hepatic
parenchyma during malaria infection (Figure 1).
CD8+ T CELLS AGAINST MALARIA LIVER STAGES ARE
DEFINED AS DIFFERENT SUBSETS AND MEDIATE
PROTECTION IN THE COURSE OF A NATURAL OR
VACCINATION-INDUCED IMMUNE RESPONSE
As in most infections caused by intracellular pathogens, CD8+
T cells are essential for developing acquired immunity against
malaria liver-stage infection (Shrikant et al., 2010; Gebhardt and
Mackay, 2012; Remakus and Sigal, 2013). Several independent
investigations have demonstrated a critical role for CD8+ T
cells in adaptive immunity against the pre-erytrocytic stage of
Plasmodium infection using different approaches, such as in vivo
depletion, reconstitution and adoptive transfer studies (Doolan
and Martinez-Alier, 2006). Former studies in experimental
rodent models indicated that immunization with irradiated
P. berghei and P. yoelli sporozoites is able to induce protec-
tive immune responses mediated by CD8+ T cells, and in vivo
depletion of this T cell subset abolished the acquired protec-
tive immunity (Schofield et al., 1987; Weiss et al., 1988; Seguin
et al., 1994; Doolan and Hoffman, 1999, 2000). Although CD8+
T cells are considered to be the primary effector cells in the
protective immune responses induced by irradiated sporozoites,
CD4+ T cells specific to parasite-epitope antigens associated with
MHC class II complexes expressed by infected hepatocytes are
also thought to exert a role in host protection (Weiss et al.,
1993).
Depending on the mouse strain used in the experimental
rodent model of malaria infection, there is a requirement for
CD4+ T cells in the effector responses induced by immuniza-
tion with irradiation-attenuated sporozoites. It has been shown
that C57BL/6, B6.129, and B10 mice immunized with irradiated
sporozoites and previously depleted of CD4+ T cells were not pro-
tected against sporozoite challenge (Doolan and Hoffman, 2000;
Doolan and Martinez-Alier, 2006). These results indicate a crit-
ical role for CD4+ T cells in the protective, immune-mediated
responses against malaria liver-stage sporozoites. However, this
CD4+ T cell requirement was not observed when BALB/c,
B10.BR, and A/J mice were infected (Doolan and Hoffman,
2000). The CD4+ T cell requirement indicates a helper function-
dependence for the induction or maintenance of effector CD8+
T cell responses, similar to how it occurs in other models. This
dependence was further investigated using CD8+ T cell receptor
(TCR) transgenic mice against the SYIPSAEKI epitope from the
Plasmodium yoelli CSP antigen (Carvalho et al., 2002).
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FIGURE 1 | Model depicting the activation of CD8+ T cells against
Plasmodium liver-stage sporozoites. Malaria is an infectious disease that
begins with the bite of an infected female Anopheline mosquito carrying the
sporozoite forms, which is the pre-erythrocytic liver stage of Plasmodium
parasites. Plasmodium sporozoites are released from the secretory duct,
where they develop, and are injected into the bite site of the skin during
blood meals. The motile sporozoites can then actively disseminate through
the skin, bloodstream and draining lymphoid tissues. It is thought that the
dendritic cell population in the skin-associated draining lymph nodes, possibly
derived from the cutaneous sites where the parasites are inoculated during
the vector bite, is critical for the priming of protective CD8+ T cells against
the Plasmodium sporozoites, which are shown to be dependent on
IL4-secreting CD4+ T helper cells. Although the epidermis and draining
lymphoid tissues are thought to initiate the priming of anti-parasite CD8+ T
cells, these effector cells can undergo further developmental steps in the
liver following stimulation with parasite antigens from sporozoites as they
develop into the erythrocytic merozoite forms of Plasmodium parasites in the
hepatic parenchyma. It has been shown that the hepatic sinusoids are
enriched with cells that are able to cross-present MHC class I antigens and
therefore act as a barrier that is specialized to process and present antigens
to intrahepatic CD8+ T cells. The liver antigen-presenting cells include
dendritic cells, sinusoidal endothelial cells as well as Kupffer cells. The vast
repertoire of antigen-presenting cells found in the journey of the parasite
from the skin to the liver could be a determinant for generating distinct CD8+
T cell subsets during infection. In fact, it has been shown that effective
protection against malaria liver stages is associated with distinct,
intra-hepatic immune responses that are characterized by the induction of
CD8+ T cell subsets with differences in the gene expression profiles
associated with the cell trafficking responses that could play roles in the local
immunity by tissue resident memory/effector cells. In the figure, the different
colored CD8+ T cells represent the heterogeneous effector populations
found in the liver following sporozoite infection.
In the TCR transgenic system, transferring of CSP-specific,
transgenic CD8+ T cells into normal mice subsequently immu-
nized with irradiation-attenuated sporozoites can induce a pro-
tective immune response against sporozoite challenge (Sano et al.,
2001). This protective response was not observed when CD8+
TCR transgenic cells were transferred into normal mice that had
been previously depleted of CD4+ T cells or IL-4 gene knockout
recipient mice (Carvalho et al., 2002). In the absence of CD4+ T
cells, effector antigen-specific CD8+ T cells begin a normal acti-
vation program with proliferative expansion in the first stages
of the T cell differentiation program. However, after this initial
phase, CD8+ TCR transgenic cells activated in the absence of
CD4+ T helper cells fail to develop further, which compromises
the effector pool of antigen-specific CD8+ T cells, as represented
by a reduced number of cells and lower frequencies of IFN-γ
secreting, antigen-specific TCR T cells. Using adoptive transfer
and reconstitution approaches with gene-knockout cells to dis-
sect the CD4+ T cell helper function, studies on the CSP-specific
CD8+ TCR transgenic system indicated a requirement for the
interleukin loop involving IL-4 receptor expression on CD8+ cells
and that IL-4 secreted by CD4+ helper T cells was necessary for
the full development of antigen-specific CD8+ T cells in the pro-
tective cellular-adaptive response against Plasmodium liver-stage
parasites (Carvalho et al., 2002; Morrot et al., 2005).
Many studies of malaria as well as listeriosis and hep-
atitis models have raised attention to the complexity of the
adaptive immune response in the hepatic microenvironment
(Shrikant et al., 2010; Condotta et al., 2012; Gebhardt and
Mackay, 2012; Claassen et al., 2013; Remakus and Sigal, 2013).
Although these studies point to a central role for CD8+ effec-
tor/memory T cells in the elimination of infectious pathogens
in the liver, the cellular and molecular interactions that under-
score the mechanisms leading to pathogen killing are still poorly
understood. In malaria, in vivo studies have investigated the
dynamics of effector CD8+ T cells in the hepatic microenviron-
ment. The immunization of naïve BALB/c mice with radiation-
attenuated sporozoites significantly increased the presence of
CD8+ T cells patrolling the sinusoids (Guebre-Xabier et al., 1999;
Cabrera et al., 2013). Importantly, studies using the TCR CSP-
specific transgenic system have approached intravital dynamic
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imaging of Plasmodium elimination and revealed that parasite
elimination frequently involves the recruitment of antigen-
specific CD8+ T cells to the liver parenchyma and the spa-
tial distribution of these cells in a cluster surrounding the
infected hepatocytes. These clusters of parasite-specific CD8+
T cells reveal an efficacious, cell-mediated protective immu-
nity mechanism against antigen targets expressed by sporozoite
forms during malaria liver-stage infection (Cockburn et al.,
2013).
Multiple effector mechanisms are likely to mediate
Plasmodium liver-stage elimination by CD8+ T cells (Frevert and
Nardin, 2008). The protective effector mechanisms exerted by
CD8+ T cells in the pre-erythrocytic malaria stages in infected
or vaccinated hosts varies depending on the infected animal
model or vaccination regimen (Doolan and Martinez-Alier,
2006; Frevert and Nardin, 2008; Duffy et al., 2012). Although the
literature has advanced our knowledge of protective host CD8+ T
cell immunity in rodent models, little is known about the cellular
events that occur in the intrahepatic malaria stage of naturally
infected humans. CD8+ T cells can induce infected host cell
killing by redundant mechanisms in which IFN-γ and TNF-α are
identified as important players of the non-cytolytic pathways of
infected hepatocytes during liver-stage infection of Plasmodium
parasites (Butler et al., 2010). Another classical mechanism is
mediated by the granule exocytosis pathway, which is a common
characteristic of CD8+ T cells and NK cells. Cytotoxic granules
are a product of the secretory lysosomes that contain the pore-
forming proteins perforin and granulysin, which are granzymes
that mediate apoptosis in target cells (Frevert and Nardin, 2008).
A preclinical trial of an optimized DNA vaccine approach that
targets multiple sporozoite and liver-stage antigens, including
CSP, LSA1, TRAP, and CelTOS, demonstrate the acquisition
of antigen-specific CD8+ granzyme B+ T cells in non-human
primates (Ferraro et al., 2013). The elimination of Plasmodium
liver-stage parasites is likely to be mediated by direct recognition
of infected hepatocytes by antigen-specific CD8+ T cells, as
this event occurs without a bystander effect that could promote
parasite killing over the distance from the synapse that is induced
between these cells in the liver parenchyma (Cockburn et al.,
2014).
The multiple effector mechanisms deployed by CD8+ T cells
against the pre-erythrocytic-stage of the Plasmodium parasite is
suggestive of a possible different commitment of the intrahepatic
CD8+ T cell lineage in malaria liver-stage infection. These cells
exhibit a transcriptional profile with a distinguishable expression
of immune function genes, cell cycle control and cell traffick-
ing (Tse et al., 2013). In fact, it has been shown that effective
protection against malaria liver stage is associated with distinct,
intra-hepatic immune responses that are characterized by the
induction of different CD8+ T cell subsets. Studies have demon-
strated that the protective T cells that are induced by attenuated
malaria parasites induce changes in the CD8+ T cell popula-
tion, which is characterized by upregulation of CD11c on effector
CD3+CD8+ T cells in the liver, spleen and peripheral blood. The
majority of these cells are CD11chiCD44hiCD62L− and secrete
pro-inflammatory cytokines and cytotoxic markers such as IFN-
γ, TNF-α, interleukin-2, perforin and CD107a. CD11c expression
is lost as the CD8+ T cells progress to memory phase (Cooney
et al., 2013).
Other studies have demonstrated that vaccine-induced immu-
nity using attenuated Plasmodium sporozoites is accompanied by
the presence of intrahepatic effector memory (EM) CD8+ T cells
characterized by a CD44hiCD45RBloCD62LloCD122lo phenotype
and central memory (CM) CD8+ T cells with a distinguished
phenotype, CD44hiCD45RBhiCD62LhiCD122hi, that are main-
tained by IL-15-mediated homeostatic proliferation (Krzych and
Schwenk, 2005). The EM CD8+ T cells promptly secrete IFN-
γ upon sporozoite challenge, and these intra-hepatic memory
CD8+ T cells can be boosted by re-exposition to sporozoite
antigens (Krzych and Schwenk, 2005). This feature could be of rel-
evance, considering that it has recently been shown that the liver
environment can keep a persisting depot of liver-stage antigens
from irradiated sporozoites over 8 weeks after immunization,
which is required for optimal development of protective immune
responses mediated by CD8+ T cells (Cockburn et al., 2010).
The presence of different T cell memory subsets may impli-
cate a self-competition of CD8+ T cells for the antigen, which,
in turn, would limit the expansion/magnitude of the EM and
CM pools of memory CD8+ T cells (Hafalla et al., 2002, 2003;
Cockburn et al., 2010). This intricate, self-regulatory mechanism
exerted by activated CD8+ T cells may have implications for the
development of malaria liver-stage vaccines, considering it has
been demonstrated that a large threshold for memory CD8+ T
cell frequencies is required for long-term protection. In these
studies, the authors have developed a model of epitope-specific
immunization regimes to induce a large memory CD8+ T cell
response capable of protecting mice from sporozoite challenges
(Schmidt et al., 2008). Although the issue concerning the per-
sistence of parasite antigens for the maintenance of memory T
cells still remains elusive as some studies have demonstrated that
primaquine treatment of immunized mice with irradiated sporo-
zoites does not affect the protective responses (Krzych et al.,
2014). However, since the primary primaquine action is target
to the pre-erytrocytic liver stage parasite development, its effect
does not interfere with the tissue depot of sporozoite antigens
responsable for the activation/maintenance of host specific T
cells (Krzych et al., 2014). Although the supporting mechanisms
responsible for the persistence of memory T cells remains still
controversial, a robust and sustainable intrahepatic CD8+ T cell
response is the target of the vaccine designs aimed at avoiding
the intrahepatic development of malaria blood-stage merozoite
forms, which are ultimately responsible for the clinical signs of the
disease. It is possible that varying the route and/or nature of the
protective antigen regimen in the prime-boost strategy implied
in the vaccine protocols would overcome this restriction. This is
of particular relevance and should be taken into consideration
because sustainable protection against malaria is characterized
by acquisition of strong, IFN-γ-secreting, intrahepatic CD8+
memory T cells (Nganou-Makamdop et al., 2012).
DEVELOPMENT OF A RECOMBINANT VACCINE AGAINST THE
PRE-ERYTHROCYTIC STAGE OF MALARIA
The only malaria vaccine that has reached Phase III clinical tri-
als consists of a recombinant version of the P. falciparum CSP
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that is administered in an adjuvant system. The efficacy of this
vaccine formulation is approximately 30–50% and greatly corre-
lates with the antibody titers to P. falciparum sporozoites and, to
a minor extent, to CSP-specific CD4+ T cells capable of secret-
ing two or more cytokines (Birkett et al., 2013). Because this
vaccine formulation already elicits antibodies and CD4+ T cell-
mediated immunity, to improve the vaccination efficacy, simulta-
neous stimulation of effector mechanisms mediated by CD8+ T
cells can be useful. Currently, the heterologous prime-boost regi-
men has achieved the best results in terms of a strong, protective
immune response mediated by CD8+ T cells specific for the pre-
erythrocytic stages of malaria parasites (Hill, 2011; Soares et al.,
2012; Teixeira et al., 2014).
Unfortunately, the results obtained after heterologous prime
boost vaccination in a mouse model have not been duplicated in
non-human primates or in humans (Birkett et al., 2013). Most
of the studies rely on the analysis of the protection efficacy from
the different vaccine regimens (Hill et al., 2010; Hill, 2011; Birkett
et al., 2013). As the protection against malaria liver stage directly
correlates with the acquisition of strong IFN-γ secreting intrahep-
atic CD8+ T cells (Nganou-Makamdop et al., 2012), the levels
of these responses elicited in the different vaccines would be an
important parameter to guide the efficiency of a vaccine design.
However, due to the absence of a direct method to identify and
phenotype malaria vaccine-induced intrahepatic CD8+ T cells in
humans and non-human primates during pre-clinical and clini-
cal tests, it should be important to determine whether the levels
of antigen-specific CD8+ T cells found in the liver correlates with
the peripheral CD8+ T cell responses from PBMC blood found in
murine models, using a subunit vaccine for proof-of-concept.
The results of clinical trials using the heterologous prime-
boost vaccination regimen with the pfcsp and pfama-1 genes were
recently published (Hill et al., 2010). This protocol consisted of
priming with recombinant plasmid DNA, followed by a booster
immunization with AdHu5, both expressing the pfcsp and pfama-
1 genes from the 3D7 strain of P. falciparum. Upon experimental
challenge by exposure to the bites of mosquitos infected with
the homologous parasite strain, only 27% of the individuals were
sterilely protected (Bruder et al., 2012).
In other studies, individuals were initially immunized with
recombinant adenoviral vector type 63 from chimpanzees that
contained a synthetic gene encoding the polypeptide denomi-
nated ME-TRAP (Sheehy et al., 2012). The individuals received
boost vaccinations with a recombinant MVA also containing this
same gene (Bejon et al., 2007). In additional heterologous prime
boost Phase II studies, 3 of 14 individuals were sterilely pro-
tected from infection after exposure to P. falciparum-infected
mosquitoes (Bejon et al., 2007).
DEVELOPMENT OF AN ATTENUATED PARASITE VACCINE AGAINST THE
PRE-ERYTHROCYTIC STAGE OF MALARIA
Although it has been long established that attenuated sporozoites
provide a high degree and relatively long-lived protective immu-
nity in most hosts, including men, vaccination regimens using
whole, attenuated sporozoites were, until recently, considered a
difficult path for the development of a product for mass vaccina-
tion. The recent development of cGMP P. falciparum sporozoite
cultivation methods has now made this path a tangible possibil-
ity (Epstein et al., 2011). This strategy offers several advantages.
Attenuated sporozoites express and present the whole spectrum
of immunogens associated with the sporozoite- and liver-stages of
malaria to the host (Butler et al., 2011; Epstein et al., 2011; Duffy
et al., 2012; Spring et al., 2013). As the attenuated parasite is still
able to infect target tissues, such as skin and liver parenchyma, in
its natural route of infection, it induces the development of spe-
cific antibodies, CD4+, CD8+, and γδ T cells. This wide range of
immunogens and mechanisms of defense has a better chance of
eliminating all pre-erythrocytic stages, which is required for ster-
ile protection. In agreement with this idea, a recent study showed
that protocols using multiple intravenous injections of radiation-
attenuated sporozoites could provide sterile, protective immunity
to 100% of vaccinated individuals (Seder et al., 2013). This obser-
vation may lead to a rational strategy for the development of a
vaccine against malaria infection. Although important challenges
should be overcome to face a large scale generation of Plasmodium
sporozoites. To this goal, the development of aseptic, purified and
cryopreserved Plasmodium falciparum sporozoites has received
important priority (Seder et al., 2013). Improvements to stabi-
lization of cryopreserved sporozoites are critically important to
maintain high infectivity for the development of a vaccine using
radiation-attenuated sporozoites. This is particularly critical to
reduce vaccine wastage by prolonging the time after thawing the
cryopreserved Plasmodium parasites during the vaccination.
SUMMARY AND PERSPECTIVES
The skin tissue acts as natural barrier against invading pathogens.
The recent advances in skin immunobiology and studies pointing
to the importance of the skin for the induction of the first signs
of an anti-Plasmodium-adaptive responses induced by CD8+
(Sinnis and Zavala, 2012)T cells against whole sporozoite forms
in natural infections have substantiated a new concept in malaria
biology and will consolidate the efforts for designing an effica-
cious vaccine against the pre-erythrocytic stages (Ménard et al.,
2013). Recent advances in rodent models indicate a parasite skin-
developmental pathway leading to generation of merozoites in
the skin hair follicles that are infective to erythrocytes (Gueirard
et al., 2010). This feature is able to promote a shortcut in the
malaria cell cycle and should reshape all the current goals for
malaria vaccine development strategies which target the induc-
tion of immunity to prevent the clinical signs of disease and/or
interrupt transmission to support the eradication of this infir-
mity. Vaccines aimed at targeting the pre-erythrocytic stages of
Plasmodium parasite infection can reach the spectrum of the
vaccine goals against malaria, as any intervention at the pre-
erythrocytic stage of the parasite cycle would have an implication
in the further development of the parasite to the blood-associated
disease symptoms and the sexual-stage parasites that are required
for vector transmission.
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